Summit Therapeutics PLC

SMMT Healthcare Biotechnology

Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00. In the quarter to June 2026, EPS grew 63.2% and free cash flow fell 112.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

14.63 0.74 −4.81%
Market cap
$12.3B
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
3/9
Altman Z
0.88
Beneish M
−5.00
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
3.80 9.87 7.41 6.96
Net Debt/EBITDA
1.02 3.12 3.16 3.13
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.13) (0.14) (0.16) (0.18)
Book value per Share
0.26 0.88 0.70 0.81
Free Cash Flow
(93.15) (102.10) (122.54) (142.03)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates